US4185100A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical anti-inflammatory drug therapy
Assignee: Johnson and Johnson
•
Filing: 1977-04-20
•
Granted: 1980-01-22
•
Expires: 1997-04-20
Abstract
Abstract A pharmaceutical composition for topical treatment of cutaneous disorders or disruptions characterized by skin inflammation or hyperproliferative epidermal activity comprises the combination of a topically active anti-inflammatory corticosteroid and a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolone derivatives; the fenamic acid derivatives; the aroyl-substituted pyrroles and the substituted arylacetohydroxamic acids in a pharmaceutically acceptable topical vehicle. Treatment of above cutaneous disorders may also be effected by concurrent therapy using separate applications of corticosteroid and non-steroid.
Inventors
- 👤 David T. Rovee
- 👤 John R. Marvel
- 👤 James A. Mezick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 13:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/60; A61K31/56; A61K31/57; A61K31/58; A61K31/618; A61K31/621; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/20; A61K9/00; A61K9/0012; A61K9/0014; A61P; A61P29/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
101 words
A method of topical treatment of an inflammatory condition of the skin comprising applying to the affected area a non-steroidal anti-inflammatory agent which is a hydratropic acid derivative selected from the group consisting of suprofen, cliprofen, cicloprofen, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen and pirprofen, and, concurrently therewith, a topically active anti-inflammatory corticosteroid, each of said hydratropic acid derivative and said corticosteroid being applied in a pharmaceutically acceptable topical vehicle selected from the group consisting of creams, gels, ointments, powders, aerosols, and solutions suitable for topical administration, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 2
Independent Claim
101 words
A method of topical treatment of an inflammatory condition of the skin comprising applying to the affected area a non-steroidal anti-inflammatory agent which is a hydratropic acid derivative selected from the group consisting of suprofen, cliprofen, cicloprofen, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen and pirprofen, and, concurrently therewith, a topically active anti-inflammatory corticosteroid, each of said hydratropic acid derivative and said corticosteroid being applied in a pharmaceutically acceptable topical vehicle selected from the group consisting of creams, gels, ointments, powders, aerosols, and solutions suitable for topical administration, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 3
Dependent Claim
29 words
The method of claim 1 wherein said corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 21-butyrate, desonide, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide and betamethasone-17-valerate.
Claim 4
Dependent Claim
11 words
The method of claim 2 wherein said corticosteroid is triamcinolone acetonide.
Claim 5
Dependent Claim
12 words
The method of claim 1 wherein said hydratropic acid derivative is suprofen.
Claim 6
Dependent Claim
12 words
The method of claim 1 wherein said hydratropic acid derivative is cliprofen.
Claim 7
Dependent Claim
17 words
The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
Claim 8
Dependent Claim
17 words
The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
Claim 9
Dependent Claim
37 words
The method of claim 6 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said topically active corticosteroid comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
Claim 10
Dependent Claim
37 words
The method of claim 6 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said non-steroidal inhibitor of prostaglandin synthetase comprising from about 0.5% to 10% by weight of suprofen.
Claim 11
Dependent Claim
22 words
The method of claim 8 wherein said non-steroidal inhibitor of prostaglandin synthetase comprises from about 0.5% to 10% by weight of suprofen.
Claim 12
Dependent Claim
87 words
A composition for the topical treatment of an inflammatory condition of the skin comprising a pharmaceutically acceptable topical vehicle selected from the group consisting of creams, gels, ointments, powders, aerosols, and solutions suitable for topical administration, said topical vehicle containing a non-steroidal anti-inflammatory agent which is a hydratropic acid derivative selected from the group consisting of suprofen, cliprofen, cicloprofen, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen and pirprofen, and a topically active anti-inflammatory corticosteroid, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 13
Dependent Claim
87 words
A composition for the topical treatment of an inflammatory condition of the skin comprising a pharmaceutically acceptable topical vehicle selected from the group consisting of creams, gels, ointments, powders, aerosols, and solutions suitable for topical administration, said topical vehicle containing a non-steroidal anti-inflammatory agent which is a hydratropic acid derivative selected from the group consisting of suprofen, cliprofen, cicloprofen, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen and pirprofen, and a topically active anti-inflammatory corticosteroid, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
Claim 14
Dependent Claim
29 words
The composition of claim 11 wherein said corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 21-butyrate, desonide, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide and betamethasone-17-valerate.
Claim 15
Dependent Claim
11 words
The composition of claim 12 wherein said corticosteroid is triamcinolone acetonide.
Claim 16
Dependent Claim
12 words
The composition of claim 11 wherein said hydratropic acid derivative is suprofen.
Claim 17
Dependent Claim
12 words
The composition of claim 11 wherein said hydratropic acid derivative is cliprofen.
Claim 18
Dependent Claim
17 words
The composition of claim 11 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
Claim 19
Dependent Claim
17 words
The composition of claim 11 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
Claim 20
Dependent Claim
38 words
The composition of claim 16 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said composition comprising as the corticosteroid from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
Claim 21
Dependent Claim
36 words
The composition of claim 16 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said composition comprising as the non-steroid from about 0.5% to 10% by weight of suprofen.
Claim 22
Dependent Claim
15 words
The composition of claim 18 wherein said concentration is from about 0.05% to about 0.1%.
Claim 23
Dependent Claim
15 words
The composition of claim 19 wherein said concentration is from about 2% to about 5%.
Claim 24
Dependent Claim
19 words
The composition of claim 18 which comprises as the non-steroid from about 0.5% to 10% by weight of suprofen.
Claim 25
Dependent Claim
22 words
A method of treating inflammatory conditions of the skin which comprises topically applying to the affected area the composition of claim 11.
References Cited (Backward Citations)
US3243344A
Cited
AU247141B2
Cited
GB1076425A
Cited
US3479396A
Cited
US3374145A
Cited
US3461208A
Cited
US3676464A
Cited
US3752826A
Cited
US3721680A
Cited
US3818048A
Cited
DE2302005A1
Cited
US4012508A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-01-21 | 1983-07-23 | 1984-01-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-01-21 | 1987-07-23 | 1988-01-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-01-21 | 1991-07-23 | 1992-01-22 | $7700.00 | Window Closed / Lapsed |